Bleeding gums: a symptom not to ignore

by Dr Nihad Pljevljak | Dec 10, 2025

Bleeding gums are a clinical warning sign that calls for a prompt professional assessment. At Nea Bios Dental Clinic in Rome EUR Laurentina, Dr Nihad Pljevljak applies advanced diagnostic protocols to identify and treat the underlying causes, preventing progression to irreversible gum disease.

Why gums bleed: the pathophysiology

Gum bleeding originates from the rupture of capillaries in the vascular network beneath the gum. Under normal conditions, the junctional epithelium forms a watertight barrier. When periodontal bacteria break through this defence, they trigger an inflammatory cascade that increases vascular permeability and capillary fragility.

Matrix metalloproteinases (MMP-8 and MMP-9) break down type I and III collagen, undermining the structural integrity of the gum's connective tissue. At the same time, pro-inflammatory cytokines (IL-1β, TNF-α, PGE2) amplify the vascular response, which shows up clinically as spontaneous or provoked bleeding.

The many causes of bleeding

Primary bacterial factors

The bacterial biofilm is the main cause. The pathogens of Socransky's red complex - Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola - produce:

Lipopolysaccharides, which stimulate the production of inflammatory mediators
Gingipains, which break down the host's proteins
Leukotoxins, which impair the local immune response

The shift from a healthy to an unbalanced (dysbiotic) microbiota is encouraged by undisturbed plaque build-up: this is why removing plaque every day is essential.

Predisposing systemic factors

Several systemic conditions increase susceptibility to bleeding:

Diabetes mellitus: chronically high blood sugar impairs neutrophil chemotaxis and increases the formation of AGEs (Advanced Glycation End-products)
Hormonal changes: pregnancy, puberty and the menopause alter the vascular response of the gums
Vitamin deficiencies: a lack of vitamin C (subclinical scurvy) and vitamin K impairs collagen synthesis and clotting factors
Blood disorders: thrombocytopenia, haemophilia and leukaemia can show up early as bleeding in the mouth

Iatrogenic and drug-related factors

Many medicines can cause or worsen bleeding:

Oral anticoagulants: warfarin (with an INR of 3.5 or above, the EFP consensus recommends consulting the treating doctor before dental care) and direct oral anticoagulants (NOACs/DOACs), which do not require INR monitoring
Antiplatelet drugs (aspirin, clopidogrel)
NSAIDs, which inhibit the synthesis of thromboxane A2
Calcium channel blockers and anti-epileptic drugs, which cause secondary gum overgrowth

Clinical classification and staging

Dr Pljevljak uses the 2017 international classification (World Workshop in Chicago, AAP/EFP) to categorise periodontal disease. Gingivitis is not divided into stages: it is defined by bleeding on probing (BOP), while stages apply only to periodontitis.

Gingivitis

Localised gingivitis: bleeding on probing (BOP) at 10% to 30% of sites
Generalised gingivitis: BOP at more than 30% of sites
No clinical attachment loss; with BOP below 10%, the gums are considered healthy

Periodontitis

Stage I: interdental CAL 1-2 mm, bone loss below 15%
Stage II: interdental CAL 3-4 mm, bone loss between 15% and 33%
Stage III: interdental CAL ≥ 5 mm, bone loss reaching the middle third of the root or beyond, up to 4 teeth lost to periodontitis
Stage IV: as stage III, but with more than 4 teeth lost to periodontitis or a need for complex rehabilitation (for example fewer than 10 pairs of opposing teeth, bite collapse, drifting teeth)

Advanced differential diagnosis

The diagnostic assessment at Nea Bios follows a systematic approach:

Clinical periodontal examination

Periodontal probing with a millimetre probe at light, controlled pressure
Bleeding index (BOP - Bleeding on Probing) at 6 sites per tooth
Gum recession measured from the CEJ to the gum margin
Tooth mobility on the Miller scale (0-III)

Microbiological diagnostics

The real-time PCR test identifies and quantifies periodontal pathogens:

Detection of pathogens such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis
An estimate of their quantity in the periodontal pockets
Information that, in selected cases, can help guide treatment

Salivary biomarkers

Analysing molecular markers in the saliva is being researched as a possible source of prognostic information, but there are no agreed cut-off values for routine clinical use yet:

Active MMP-8, associated with tissue destruction
Calprotectin, studied as a marker of inflammation
IL-1 gene variants, proposed as risk markers with inconsistent results

Evidence-based treatment protocols

Non-surgical cause-related therapy

The initial treatment aims to eliminate the biofilm:

Full-mouth instrumentation within 24 hours or quadrant by quadrant: the EFP guideline considers them equivalent options
Scaling and root planing with piezoelectric ultrasonic scalers and Gracey curettes
Air-polishing with glycine to remove biofilm above the gum line
Laser therapy only in selected cases: the EFP guideline does not suggest its routine use in addition to instrumentation

In selected cases, locally applied sustained-release antiseptics or antibiotics (for example chlorhexidine-based products) may be considered; the EFP guideline lists them as options to be assessed case by case.

Systemic antibiotic therapy

Not recommended routinely: the EFP guideline reserves it for specific groups of patients, for example generalised stage III periodontitis in young adults:

Amoxicillin + metronidazole, with dose and duration set by the clinician
For allergic patients, alternatives assessed case by case
Always as an addition to mechanical removal of the biofilm

Periodontal regenerative therapy

For intrabony defects, Dr Pljevljak uses regenerative techniques:

EMD (Enamel Matrix Derivative) to regenerate the periodontal tissues
Bone grafts with Bio-Oss® and resorbable collagen membranes
PRGF (Plasma Rich in Growth Factors) in selected cases, to support healing

Therapeutic innovations and future approaches

Antimicrobial photodynamic therapy (aPDT)

Applying photosensitisers (methylene blue, indocyanine green) activated by a diode laser has been studied as an addition to treatment:

Aim: to reduce the bacterial load in the periodontal pockets
The additional clinical benefits seen in studies are limited
For this reason, the EFP guideline advises against its routine use

Periodontal probiotics

Supplementation with Lactobacillus reuteri and other probiotic strains is being researched:

Hypothesis: rebalancing the oral microbiota
Results from clinical studies are still limited
The EFP guideline does not suggest using them in addition to periodontal treatment

Cell-based regenerative medicine

Mesenchymal stem cells from the periodontal ligament are being studied in the laboratory and in early trials, not yet as a routine treatment, for:

Regeneration of the tooth's supporting apparatus
Formation of new cementum, ligament and alveolar bone
Controlled formation of new blood vessels in healing tissue

Prevention and periodontal maintenance

Long-term success requires a structured programme:

Optimised home care

Brushing with the modified Bass technique, 2 minutes twice a day
Interdental brushes sized for each space, recommended by the EFP guideline where the space allows
Water flossers with periodontal tips, if advised by the clinician
Mouthwashes with CPC (cetylpyridinium chloride) for chemical control

Supportive Periodontal Therapy (SPT)

Personalised recalls based on individual risk; the EFP guideline recommends intervals of 3 to a maximum of 12 months:

Low risk: longer intervals, up to 12 months
Moderate risk: intermediate intervals, set by the clinician
High risk: shorter intervals, every 3-4 months in many studies

Each session includes a full periodontal re-evaluation, renewed motivation and reinforcement of hygiene techniques.

Systemic links of gum disease

Studies document associations between periodontitis and several systemic diseases (with diabetes the relationship works both ways):

Cardiovascular disease: periodontitis is independently associated with a higher risk of heart attack and stroke; estimates of its size vary between studies
Diabetes: HbA1c is higher in diabetic patients with periodontitis; periodontal treatment is associated with HbA1c reductions of about 0.27-0.48% after 3 months
Premature birth: an association with pregnancy complications, including premature birth
Rheumatoid arthritis: a documented association, with inflammatory mechanisms still being studied
Alzheimer's disease: P. gingivalis and its proteases (gingipains) have been identified in the brain tissue of people with Alzheimer's; whether they play a causal role is still being researched

This interconnection underlines the importance of treating bleeding gums promptly.

For more information, see also: /en/gum-disease-periodontitis-treatment/

When bleeding needs immediate attention

Warning signs that call for an urgent assessment:

Spontaneous bleeding at night
Heavy bleeding, or bleeding that does not stop quickly after brushing
Bleeding together with fever, general malaise or swollen lymph nodes
Ulcers or growths in the mouth
Bleeding after minimal trauma in a patient on anticoagulants

Dr Nihad Pljevljak, drawing on his PhD in Oral and Dental Diseases from Sapienza University and his experience with high-profile patients in the EUR district, offers a thorough assessment and a personalised treatment plan.

Don't neglect bleeding gums: book a full periodontal assessment at Nea Bios Dental Clinic today. Our reception is open Monday to Friday from 9:00 to 13:00 and 14:00 to 18:00 to arrange an urgent or routine appointment at Via Cesare Pavese 135, Rome EUR Laurentina. Prevention today means health tomorrow.

Sources

Sanz M, Tonetti M. Periodontitis: clinical decision tree for staging and grading. Guidance for clinicians. European Federation of Periodontology; 2019. EFP
Sanz M, Herrera D, Kebschull M, et al. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020;47 Suppl 22:4-60. PubMed
Sanz M, Marco Del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular diseases: Consensus report. J Clin Periodontol. 2020;47(3):268-288. PubMed
Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J Clin Periodontol. 2018;45(2):138-149. PubMed
Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: An overview. Periodontol 2000. 2020;83(1):7-13. PubMed
Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333. PubMed